{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002132","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.799411+00:00","generated_at":"2026-06-19T21:49:18.488541+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atara reports FY2022 net loss $228.3M, CFO transition, Ebvallo EU launch","bullets":["Cash and investments $242.8M as of Dec 31, 2022; runway extended into Q2 2024.","Net loss $228.3M ($2.24/share) for FY2022 vs $340.1M ($3.63/share) in FY2021.","CFO Utpal Koppikar resigns effective March 31, 2023; Eric Hyllengren appointed CFO effective April 1, 2023.","Ebvallo EU launch led by Pierre Fabre to begin Q1 2023; FDA discussions ongoing for tab-cel BLA.","ATA188 Phase 2 EMBOLD primary data readout on track for October 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002132","json":"https://secwatch.observer/filing/0000950170-23-002132.json","markdown":"https://secwatch.observer/filing/0000950170-23-002132.md","text":"https://secwatch.observer/filing/0000950170-23-002132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/atra-20230203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T21:49:18.488541+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab1f2074f14c6af84017be37aac8163410fa1fa0","claim":"Atara Biotherapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income $74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the fourth quarter and fiscal year 2022, EPS $0.72 per share, and ... $2.24 per share.","evidence_excerpt":"On February 8, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”) announced certain financial results for the fourth quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm","confidence":0.75,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"$74.6 million, or $0.72 per share, and $228.3 million, or $2.24 per share, for the fourth quarter and fiscal year 2022"},{"label":"EPS","value":"$0.72 per share, and ... $2.24 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"1f50782d9e","claim":"Utpal Koppikar resigned as Executive Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..","evidence_excerpt":"Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company, effective March 31, 2023, to pursue an external opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"9e44053c7d","claim":"Eric Hyllengren was appointed as Senior Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..","evidence_excerpt":"the Company appointed Eric Hyllengren, the Company’s Senior Vice President, Finance, to serve as the Company’s Senior Vice President, Chief Financial Officer, effective as of April 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023002132/0000950170-23-002132-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Senior Vice President, Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}